Ocugen licenses OCU400 to Celairis for Australia, New Zealand and ASEAN markets
Ocugen granted Celairis Therapeutics an exclusive, royalty-bearing license to commercialize its investigational gene therapy OCU400 for retinitis pigmentosa in eight named markets, including Australia, New Zealand, Singapore and Indonesia. Ocugen will receive up to $7.1 million in fees and milestone payments, plus a high-single-digit percentage royalty on net sales and 50% of gross profits, while retaining the sole right to manufacture the product in the territory.
Key points
- Territory: Australia, Singapore, New Zealand, Malaysia, Thailand, Philippines, Vietnam and Indonesia, with possible expansion by mutual agreement
- Up to $6.1 million, including an up-front fee and a fee payable on positive Phase 3 LiMeliGhT topline results; a $1.0 million milestone is payable on Australian Therapeutic Goods Administration approval
- Ocugen receives a high-single-digit percentage royalty on net sales and 50% of gross profits; a supply agreement is targeted within 90 days
- License runs until the latest of 20 years after first commercial sale, patent expiry, or regulatory exclusivity expiry
The filing
Written by AI on Nov 10, 2026, 8:40 AM ET, from this filing only.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.